**Supplemental table**

|  |
| --- |
| Table e1. Differences in CSF Tau and pTau concentrationsin men compared to womenstratified per clinical diagnosis and APOE e4 genotype.  |
|  | Tau | pTau |
|  | Adjusted mean difference $β$(se)a | Effect size (95%CI) | *p*-value | Adjusted*p*-value | Adjusted mean difference $β$(se)a | Effect size (95%CI) | *p*-value | Adjusted*p*-value |
| APOE e2 carrier | SCD | 0.12 (0.13) | -0.16 (-0.77- -0.45) | 0.38 | >0.05 | 0.11 (0.11) | -0.20 (-0.83-0.43) | 0.31 | >0.05 |
|  | MCI | -0.31 (0.20) | 0.60 (-0.14-1.34) | 0.11 | >0.05 | -0.37 (0.16) | 0.78 (0.03-1.54) | 0.02 | 0.36 |
|  | AD  | -0.25 (0.19) | 0.53 (0.19-1.24) | 0.20 | >0.05 | -0.15 (0.15) | 0.37 (-0.33-1.08) | 0.31 | >0.05 |
| APOE e3 carrier | SCD | 0.04 (0.06) | -0.05 (-0.32- 0.22) | 0.52 | >0.05 | 0.01 (0.05) | 0.008 (-0.26-0.28) | 0.82 | >0.05 |
|  | MCI | -0.25 (0.10) | 0.46 (0.11-0.81) | 0.01 | 0.17 | -0.19 (0.08) | 0.40 (0.05-0.75) | 0.02 | 0.36 |
|  | AD  | 0.24 (0.07) | 0.42 (0.17-0.66) | <0.001 | 0.009 | -0.17 (0.05) | 0.39 (0.14-0.63) | 0.002 | 0.04 |
| APOE e4 carrier | SCD | 0.33 (0.08) | 0.64 (0.29-0.98) | <0.001 | 0.002 | -0.22 (0.06) | 0.56 (0.21-0.90) | <0.001 | 0.005 |
|  | MCI | 0.29 (0.07) | 0.52 (0.25-0.79) | <0.001 | 0.002 | -0.21 (0.06) | 0.49 (0.23-0.76) | <0.001 | 0.02 |
|  | AD  | 0.07 (0.04) | 0.14 (-0.02- 0.30) | 0.11 | >0.05 | -0.03 (0.04) | 0.07 (-0.09-0.23) | 0.41 | >0.05 |
| Differences in CSF Tau and pTau for women and men stratified per APOE e4 genotype and clinical diagnosis. Tau and pTau were log transformed to meet assumptions of normality. We performed GLM in CSF biomarker concentrations stratified for APOE genotype and clinical disease stage as shown in figure 1. These analyses included sex as a factor and age as covariate. Cohen’s d statistics were used to calculate effect sizes: small=0.2, medium= 0.5, large= 0.8. *p* <0.05 is considered significant. a Reference is female sex.  b Adjustments for age at time of lumbar puncture. Abbreviations: APOE, Apolipoprotein E4; SCD, Subjective Cognitive Decline; MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; MMSE, Mini Mental State Exam; 95% CI, 95% Confidence Interval. |